Mackenzie Financial’s NovoCure NVCR Stock Holding History

Mackenzie Financial’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$734K	Buy	+48,472	New	+$733K	﹤0.01%	1245
2025 Q3	–	Sell	-66,152	Closed	-$1.18M	–	1798
2025 Q2	$1.18M	Buy	+66,152	New	+$1.15M	﹤0.01%	973
2025 Q1	–	Sell	-6,820	Closed	-$203K	–	1759
2024 Q4	$203K	Buy	+6,820	New	+$144K	﹤0.01%	1562
2022 Q1	–	Sell	-12,078	Closed	-$907K	–	1476
2021 Q4	$907K	Buy	12,078 +4,620	+62%	+$464K	﹤0.01%	921
2021 Q3	$866K	Buy	7,458 +3,282	+79%	+$496K	﹤0.01%	927
2021 Q2	$926K	Buy	+4,176	New	+$812K	﹤0.01%	891
2018 Q2	–	Sell	-23,600	Closed	-$514K	–	1042
2018 Q1	$514K	Buy	+23,600	New	+$508K	﹤0.01%	729

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Mackenzie Financial's NVCR Position: Q2 2026 in Review

Mackenzie Financial opened a new position in NovoCure (NVCR) in Q2 2026: 48,472 shares worth $734K. The stake represents ﹤0.01% of the portfolio and ranks #1245 among its holdings. This is a return to the name: Mackenzie Financial previously reported a position in NVCR as recently as Q2 2025.

Mackenzie Financial first reported a position in NVCR in Q1 2018 and has held it in 7 quarters since. The position peaked at $1.18M in Q2 2025. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Mackenzie Financial held 48,472 shares of NovoCure worth $734K as of Q2 2026.
NovoCure was a new Mackenzie Financial position in Q2 2026.
NovoCure made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #1245 holding.
Mackenzie Financial first reported a position in NovoCure in Q1 2018 and has held it in 7 quarters since.
Mackenzie Financial's NovoCure position peaked at $1.18M in Q2 2025.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.